Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s showed a potential therapeutic effect of psilocybin for patients affected by depressive symptoms, anxiety, and conversion disorder. Psilocybin was classed as a schedule I substance in 1970, but the fascination with psychedelics has remained almost unchanged over time, promoting a new scientific interest starting in the 1990s. Recent studies have provided further evidence supporting the suggestive hypothesis of the therapeutic use of psilocybin for treating various psychiatric disorders, including pathological anxiety, mood depressive disorder, and addiction.

Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder characterised by core symptoms of impulsivity, locomotor hyperactivity, and inattention affecting around 5% of children and adolescents worldwide. Although this brain illness is wrongly considered a childhood disorder, increasing evidences suggest that it can persist into adulthood in about 65% of cases leading to significant clinical, socio-relational, and occupational disabilities. Pharmacological and non-pharmacological treatments currently available permit to achieve numerous benefits, in particular, if started early in childhood, however, quality of life of patients affected by ADHD could be compromised in any case in terms of self-esteem, ability to finalize projects, and personal satisfaction. In this study we evaluated the impact of micronutrient formulations on ADHD symptoms in both children and adults analyzing results of randomized, placebo-controlled trials.

Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s have shown a potential therapeutic effect of psilocybin in patients affected by depressive symptoms, anxiety, and conversion disorder. Psilocybin was classed as a schedule I substance in 1970, but the fascination for psychedelics remained almost unchanged over time promoting a new scientific interest starting from the 1990s. Recent studies provided further evidences supporting the suggestive hypothesis of a therapeutic use of psilocybin for treating various psychiatric disorders including: pathological anxiety, mood depressive disorder and addiction.